US Patent

US11504370 — Treatment of brain cancer

Method of Use · Assigned to Array Biopharma Inc · Expires 2033-03-25 · 7y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects the use of certain compounds for treating brain cancer.

USPTO Abstract

Compounds for the treatment of brain cancer are provided herein. Pharmaceutical compositions comprised of those compounds for the treatment of brain cancer are also provided herein.

Drugs covered by this patent

Tukysa (tucatinib) · Seagen

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2788`	—	Tukysa
`U-2788`	—	Tukysa

Patent Metadata

Patent number: US11504370
Jurisdiction: US
Classification: Method of Use
Expires: 2033-03-25
Drug substance claim: No
Drug product claim: No
Assignee: Array Biopharma Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.